Maze Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.75B
- P/E (TTM)
- –
- Dividend yield
- –
About Maze Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Maze Therapeutics is a clinical-stage biopharmaceutical company that develops small molecule precision medicines for individuals affected by kidney and metabolic disorders. The company identifies and characterizes genetic variants through its proprietary Compass platform to understand disease risk and guide drug development. Its pipeline includes investigational candidates such as MZE829, an oral inhibitor targeting APOL1-mediated kidney disease, and MZE782, alongside partnered assets like MZE001. The company focuses on patient populations suffering from conditions such as chronic kidney disease and engages biopharmaceutical collaborators through licensing agreements.
The enterprise is based in South San Francisco, California, where it maintains its principal executive offices. Its operational reach within the United States and abroad involves partnerships with research consortiums, including collaborations in Finland and the United Kingdom. Because its drug candidates remain in clinical and preclinical development, Maze Therapeutics maintains research facilities rather than commercial treatment centers or retail locations, and it conducts its trials through third-party clinical research and manufacturing organizations.
Summary of the business section of Maze Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Maze Therapeutics, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 171 Oyster Point Boulevard, Suite 300 94080
- Phone
- (650) 850-5070
- Employees
- 141, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- MAZE
- Exchange
- Nasdaq
- IPO date
- Jan 31, 2025
- Shares outstanding
- 56M, Aug 5, 2026
- Public float
- $443.90M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1842295
- CUSIP
- 578784100
- ISIN
- US5787841007
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jason V. Coloma | Chief Executive Officer, Director | 268,997 |
| Harold Bernstein | President, R&D & CMO | 0 |
| Atul Dandekar | CSBO | 32,316 |
| Phillips Courtney | GC and Corp. Secretary | 7,007 |
| Amy Bachrodt | SVP, Finance | 15,465 |
| Misbah Tahir | Chief Financial Officer | – |
| Paula A. Johnson | Director | – |
| Sophie Kornowski | Director | – |
| Richard H. Scheller | Director | 0 |
| Herve Hoppenot | Director | – |
| Jonathan E. Lim | Director | 328,700 |
| Daniel K. Spiegelman | Director | – |
| Charles J. Homcy | Director | 38,535 |
| Nancy C. Andrews | Director | – |
| Neil Kumar | Director | – |
| Catherine A. Sohn | Director | 20,744 |
| Sekar Kathiresan | Director | 103,723 |
| Neil Exter | Director | – |
| James Brush | Director | – |
| Jeffrey K. Tong | Director | – |
| Alan Colowick | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 141 employees, all of whom were full-time and 108 of whom were engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 31, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 27, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |